Dexamethasone 21-sulfate improves the therapeutic properties of dexamethasone against experimental rat colitis by specifically delivering the steroid to the large intestine

Pharmaceutical Research

Volumn 26, Issue 2, 2009, Pages 415-421

  Kim, Inho ^a   Kong, Hyesik ^b   Lee, Younghyun ^a   Hong, Sungchae ^a   Han, Jungoh ^a   Jung, Sunhwa ^a   Jung, Yunjin ^a   Kim, Young Mi ^a  

^a Pusan National University   (South Korea)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Colon specific prodrug; Dexamethasone; Dexamethasone 21 sulfate; Inflammatory bowel disease; Systemic adverse effect

Indexed keywords

CORTICOSTERONE; CORTICOTROPIN; DEXAMETHASONE; DEXAMETHASONE 21 SULFATE; PRODRUG; UNCLASSIFIED DRUG;

ADRENAL SUPPRESSION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DISEASE MODEL; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FECES LEVEL; DRUG FORMULATION; DRUG URINE LEVEL; INTESTINE FLUID; LARGE INTESTINE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; THERAPY EFFECT;

ADMINISTRATION, ORAL; ADRENAL GLANDS; ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANTI-INFLAMMATORY AGENTS; COLITIS; COLON; DEXAMETHASONE; DISEASE MODELS, ANIMAL; FECES; GASTROINTESTINAL AGENTS; HYDROCORTISONE; INTESTINAL ABSORPTION; MALE; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; SULFATES; TRINITROBENZENESULFONIC ACID;

EID: 58549101264     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-008-9758-1     Document Type: Article

References (20)

1. D. K. Podolsky 1991 Inflammatory bowel disease (1) N. Engl. J. Med. 325 928 37
2. D. K. Podolsky 1991 Inflammatory bowel disease (2) N. Engl. J. Med. 325 1008 16
3. R. J. Xavier D. K. Podolsky 2007 Unravelling the pathogenesis of inflammatory bowel disease Nature 448 427 34
4. B. Crotty D. P. Jewell 1992 Drug therapy of ulcerative colitis Br. J. Clin. Pharmacol. 34 189 98
5. M. Robinson 1998 Medical therapy of inflammatory bowel disease for the 21st century Eur. J. Surg. Suppl. 582 90 8
6. E. Domenech 2006 Inflammatory bowel disease: current therapeutic options Digestion 73 Suppl 1 67 76
7. D. R. Friend G. W. Chang 1985 Drug glycosides: potential prodrugs for colon-specific drug delivery J. Med. Chem. 28 51 7
8. A. D. McLeod L. Tolentino T. N. Tozer 1994 Glucocorticoid-dextran conjugates as potential prodrugs for colon-specific delivery: steady-state pharmacokinetics in the rat Biopharm. Drug Dispos. 15 151 61
9. H. Yano F. Hirayama H. Arima K. Uekama 2001 Preparation of prednisolone-appended alpha-, beta- and gamma-cyclodextrins: substitution at secondary hydroxyl groups and in vitro hydrolysis behavior J. Pharm. Sci. 90 493 503
10. Y. J. Jung M. J. Doh I. H. Kim H. S. Kong J. S. Lee Y. M. Kim 2003 Prednisolone 21-sulfate sodium: a colon-specific pro-drug of prednisolone J. Pharm. Pharmacol. 55 1075 82
11. I. H. Kim H. S. Kong B. I. Choi Y. S. Kim H. J. Kim Y. W. Yang Y. J. Jung Y. M. Kim 2006 Synthesis and in vitro properties of dexamethasone 21-sulfate sodium as a colon-specific prodrug of dexamethasone Drug Dev. Ind. Pharm. 32 389 97
12. V. R. Sinhaand R. Kumria 2001 Colonic drug delivery: prodrug approach Pharm. Res. 18 557 64
13. A. Rubinstein 1990 Microbially controlled drug delivery to the colon Biopharm. Drug. Dispos. 11 465 75
14. H. Yano F. Hirayama M. Kamada H. Arima K. Uekama 2002 Colon-specific delivery of prednisolone-appended alpha-cyclodextrin conjugate: alleviation of systemic side effect after oral administration J. Control Release. 79 103 12
15. G. P. Morris P. L. Beck M. S. Herridge W. T. Depew M. R. Szewczuk J. L. Wallace 1989 Hapten-induced model of chronic inflammation and ulceration in the rat colon Gastroenterology. 96 795 803
16. M. W. Son J. I. Ko H. M. Doh W. B. Kim T. S. Park M. J. Shim B. K. Kim 1998 Protective effect of taurine on TNBS-induced inflammatory bowel disease in rats Arch. Pharm. Res. 21 531 6
17. S. Y. Zhou D. Fleisher L. H. Pao C. Li B. Winward E. M. Zimmermann 1999 Intestinal metabolism and transport of 5-aminosalicylate Drug Metab. Dispos. 27 479 85
18. D. R. Friend 1998 Review article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease Aliment. Pharmacol. Ther. 12 591 603
19. U. Fagerholm A. Lindahl H. Lennernas 1997 Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms J. Pharm. Pharmacol. 49 687 90
20. L. Kagan A. Hoffman 2008 Systems for region selective drug delivery in the gastrointestinal tract: biopharmaceutical considerations Expert Opin. Drug. Deliv. 5 681 692